1. Search Result
Search Result
Results for "

influenza A

" in MCE Product Catalog:

174

Inhibitors & Agonists

3

Screening Libraries

22

Peptides

37

Natural
Products

339

Recombinant Proteins

15

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-149034
    Influenza A virus-IN-8

    S5

    Influenza Virus Infection
    Influenza A virus-IN-8 (S5) is a macrocyclic peptide with no cytotoxic. Influenza A virus-IN-8 is also a potent Influenza A Virus (IAV) inhibitor (with sufficient protease stability) with IC50s of 6.7 and 6.6 nM for H1 and H5 variants, respectively. Influenza A virus-IN-8 shows good affinitiescan to H1 variants, binds to a conserved region in the HA stem with a Kd of 1.0 nM.
  • HY-146004
    Influenza A virus-IN-4

    Influenza Virus Infection
    Influenza A virus-IN-4 (compound 23b), an Oseltamivir derivative, is a potent inhibitor of neuraminidase. Influenza A virus-IN-4 exerts powerful inhibitions on influenza viruses.
  • HY-146361
    Influenza A virus-IN-7

    Influenza Virus Inflammation/Immunology
    Influenza A virus-IN-7 (compound 16r) is a potent and orally active influenza A virus inhibitor with an IC50 of 3.43 µM and CC50 of >100 µM. Influenza A virus-IN-7 shows anti-IAV activity with low cytotoxicity. Influenza A virus-IN-7 inhibits the transcription and replication of viral RNA.
  • HY-146359
    Influenza A virus-IN-5

    Influenza Virus DNA/RNA Synthesis Infection
    Influenza A virus-IN-5 (Compound 16e) is a potent, orally active anti-influenza A virus (IAV) agent with an IC50 of 1.29 μM. Influenza A virus-IN-5 inhibits the transcription and replication of viral RNA with acceptable cytotoxicity.
  • HY-146360
    Influenza A virus-IN-6

    Influenza Virus Inflammation/Immunology
    Influenza A virus-IN-6 (compound 16j) is a potent and selective influenza A virus inhibitor with an IC50 of 3.88 µM and CC50 of 36.64 µM. Influenza A virus-IN-6 shows anti-IAV activity with low cytotoxicity.
  • HY-131179
    Influenza A virus-IN-1

    Influenza Virus Infection
    Influenza A virus-IN-1 is a dihydropyrrolidones derivative and is a potent inhibitor against wide subtypes of influenza A virus (IAV) with IC50 values from 3.11 μM to 7.13 μM. Influenza A virus-IN-1 efficiently inhibits replication of IAV, up-regulates the expression of key antiviral cytokines IFN-β and antiviral protein MxA.
  • HY-P1788
    Influenza A NP(366-374) Strain A/PR/8/35

    Influenza Virus Infection
    Influenza A NP(366-374) Strain A/PR/8/35 is an H2-Db-restricted epitope from Influenza A/PR/8/35 nucleoprotein.
  • HY-112543
    S119-8

    Influenza Virus Infection
    S119-8 is a broad spectrum inhibitor of influenza A and B viruses, showing activity against multiple influenza B viruses and an oseltamivir-resistant influenza A virus, but does not inhibit a non-influenza virus, vesicular stomatitis nirus (VSV).
  • HY-143752
    Cap-dependent endonuclease-IN-8

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-8 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-8 inhibits replication of orthomyxoviruses (including influenza A, influenza B and influenza C) (extracted from patent CN111410661A, compound I-196).
  • HY-144066
    Cap-dependent endonuclease-IN-21

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-21 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-21 inhibits the replication of influenza virus. ap-dependent endonuclease-IN-21 has the potential for the research of influenza virus infection (influenza A) (extracted from patent WO2021233302A1, compound 8B or 8A).
  • HY-144067
    Cap-dependent endonuclease-IN-23

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-23 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-23 inhibits the replication of influenza virus. ap-dependent endonuclease-IN-23 has the potential for the research of influenza virus infection (influenza A) (extracted from patent WO2021233302A1, compound 8A or 8B).
  • HY-143766
    Cap-dependent endonuclease-IN-13

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-13 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-13 has the potential for the research of influenza virus infection (only influenza A) (extracted from patent WO2021180147A1, compound I-1).
  • HY-143744
    Cap-dependent endonuclease-IN-3

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-3 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-3 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-3 has the potential for the research of influenza A and influenza B infection (extracted from patent WO2019141179A1, compound VI-1).
  • HY-143750
    Cap-dependent endonuclease-IN-7

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-7 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-7 Inhibits the synthesis of viral mRNA and eventually inhibits virus proliferation. Cap-dependent endonuclease-IN-7 has the potential for the research of viral infections (including influenza A, influenza B and influenza C) (extracted from patent WO2020177715A1, compound 5)
  • HY-131069A
    MBX2329

    Influenza Virus Infection
    MBX2329, a potent influenza virus inhibitor, specifically inhibits hemagglutinin (HA)-mediated viral entry with HIV/HA(H5) displaying IC90 of 8.6 μM. MBX2329 inhibits a wide spectrum of influenza A viruses, which includes the 2009 pandemic influenza virus A/H1N1/2009, highly pathogenic avian influenza (HPAI) virus A/H5N1, and oseltamivir-resistant A/H1N1 strains.
  • HY-143781
    Cap-dependent endonuclease-IN-26

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-26 is a cap-dependent endonuclease (CEN) inhibitor with an IC50 of 286 nM. Cap-dependent endonuclease-IN-26 shows antiviral activity against many influenza A and B strains.
  • HY-143495
    RSV-IN-3

    RSV Influenza Virus Infection
    RSV-IN-3 (Compound 1) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza virus A (IAV). RSV-IN-3 shows anti-RSV activity (EC50 = 32.70 μM).
  • HY-143496
    RSV-IN-4

    RSV Influenza Virus Infection
    RSV-IN-4 (Compound 2) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza virus A (IAV). RSV-IN-4 shows anti-RSV activity (EC50 = 11.76 μM).
  • HY-N0035
    Arctigenin

    (-)-Arctigenin

    MMP Influenza Virus Autophagy Apoptosis Cancer Infection Metabolic Disease Inflammation/Immunology Neurological Disease
    Arctigenin ((-)-Arctigenin), a biologically active lignan, can be used as an antitumor agent. Arctigenin exhibits potent antioxidant, anti-inflammatory and antiviral (influenza A virus) activities. Arctigenin can be used for the research of metabolic disorders, and central nervous system dysfunctions.
  • HY-W011518
    2′-Deoxy-2′-fluoroguanosine

    Influenza Virus Infection
    2′-Deoxy-2′-fluoroguanosine, a nucleoside analog, is a potent inhibitor of influenza virus strains, with an EC90 of <0.35 μM for influenza virus A and B strains. 2′-Deoxy-2′-fluoroguanosine significantly inhibits replication of influenza virus in the upper respiratory tract, resulting in amelioration of fever and nasal inflammation.
  • HY-147881
    Anti-Influenza agent 3

    Influenza Virus Infection
    Anti-Influenza agent 3 (compound 11h) is a potent anti-influenza agent with EC50 values of 3.29, 2.45 µM for A/HK/68 (H3N2, M2-WT), A/WSN/33 (H1N1, M2-S31N) strain, respectively. Anti-Influenza agent 3 shows low cytotoxicity for MDCK epithelial cells. Anti-Influenza agent 3 inhibits the M2 WT and S31N ion channel conductivity.
  • HY-131059
    CBS1117

    Influenza Virus Infection
    CBS1117 is a virus entry inhibitor with an IC50 of 70 nM for influenza A virus, A/Puerto Rico/8/34 (H1N1). CBS1117 interferes with the hemagglutinin (HA)-mediated fusion process.
  • HY-134922
    NS1-IN-1

    Influenza Virus Infection
    NS1-IN-1 (compound 3) is a potent NS1 inhibitor. NS1 is a major influenza A virus virulence factor that inhibits host gene expression. NS1-IN-1 decreases viral protein levels, contributing to the reduction of virus replication. NS1-IN-1 shows antiviral activity by repressing the activity of mTORC1 in a TSC1-TSC2-dependent manner.
  • HY-143755
    Cap-dependent endonuclease-IN-9

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-9 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-9 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-9 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent CN112521386A, compound VI-1).
  • HY-143743
    Cap-dependent endonuclease-IN-2

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-2 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-2 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-2 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent WO2019052565A1, compound 28).
  • HY-143494
    RSV/IAV-IN-3

    RSV Influenza Virus Infection
    RSV/IAV-IN-3 (compound 14'i) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza A virus (IAV) with EC50 values of 2.92 µM and 1.90 µM,respectively. RSV/IAV-IN-3 has antiviral effect against H1N1 and H3N2 with EC50 values of 3.25 µM and 1.50 µM in MDCK cells, respectively. RSV/IAV-IN-3 significantly inhibits the activity of luciferase in a dose-dependent manner, with an EC50 of 3.89 µM. RSV/IAV-IN-3 inhibits IAV infectivity and RdRp activity. RSV/IAV-IN-3 inhibits IAV and RSV replication at the post-entry stage.
  • HY-P1749
    Influenza HA (307-319)

    Influenza Virus Infection
    Influenza HA (307-319) is 13 amino acids 307 to 319 fragment of Influenza HA. Influenza HA is a glycoprotein found on the surface of influenza viruses.
  • HY-N2216
    Polygalasaponin XXXI

    Onjisaponin F

    Influenza Virus Infection
    Polygalasaponin XXXI (Onjisaponin F) is an effective adjuvant for intranasal administration of influenza Influenza hemagglutinin (HA) vaccine to protect influenza virus infection.
  • HY-143493
    Influenza virus-IN-2

    Influenza Virus Inflammation/Immunology
    Influenza virus-IN-2 (compound 19) is a potent influenza virus inhibitor with an EC50 of 2.58 µM and CC50 of 150.85 µM. Influenza virus-IN-2 shows a concentration dependent inhibition activity for PAN endonuclease with EC50 of 489.39 nM. Influenza virus-IN-2 shows shows anti-influenza A virus activities.
  • HY-143492
    Influenza virus-IN-1

    Influenza Virus Inflammation/Immunology
    Influenza virus-IN-1 (compound 14) is a potent influenza A virus inhibitor with an EC50 of 2.46 µM and CC50 of >200 µM. Influenza virus-IN-1 shows a concentration dependent inhibition activity for PAN endonuclease with EC50 of 312.36 nM. Influenza virus-IN-1 shows shows anti-influenza A virus activities.
  • HY-P1762
    Influenza NP (147-155)

    Influenza Virus Infection
    Influenza NP (147-155) is a K d restricted epitope from influenza nucleoprotein.
  • HY-146147
    Influenza virus-IN-5

    Influenza Virus Infection
    Influenza virus-IN-5 (Compound 5f) is an inhibitor of influenza virus hemagglutinin (HA) with an EC50 of 1 nM against influenza A/H3N2 virus.
  • HY-P1762A
    Influenza NP (147-155) (TFA)

    Influenza Virus Infection
    Influenza NP (147-155) TFA is a K d restricted epitope from influenza nucleoprotein.
  • HY-P1580
    PA (224-233), Influenza

    Influenza Virus Infection
    PA (224-233), Influenza is a 10-aa peptide, a fragment of polymerase 2 protein in influenza A virus.
  • HY-13210
    Zanamivir

    Influenza Virus Antibiotic Infection
    Zanamivir is an influenza viral neuraminidase inhibitor with IC50 values of 0.95 nM and 2.7 nM for influenza A and B, respectively.
  • HY-P0137
    CEF1, Influenza Matrix Protein M1 (58-66)

    Influenza Virus Infection
    CEF1, Influenza Matrix Protein M1 (58-66) is an epitope derived from the matrix protein of the influenza A virus.
  • HY-14818A
    Laninamivir octanoate

    CS-8958

    Influenza Virus Infection
    Laninamivir octanoate (CS-8958), a prodrug of Laninamivir, is a long-acting neuraminidase (NA) inhibitor with anti-influenza virus activity. Laninamivir octanoate shows anti-influenza activity against Oseltamivir-resistant viruses, and also against the pandemic influenza viruses.
  • HY-P1783
    M2e, human

    Influenza Virus Infection
    M2e, human, consisting of the 23 extracellular residues of M2 (the third integral membrane protein of influenza A), has been remarkably conserved in all human influenza A, which is a valid and versatile vaccine candidate to protect against any strain of human influenza A.
  • HY-13210A
    Zanamivir (hydrate)(5:1)

    Antibiotic Influenza Virus Infection
    Zanamivir hydrate (5:1) is the hydrate of Zanamivir. Zanamivir is an influenza viral neuraminidase inhibitor with IC50 values of 0.95 nM and 2.7 nM for influenza A and B, respectively.
  • HY-146001
    Influenza virus-IN-4

    Influenza Virus Inflammation/Immunology
    Influenza virus-IN-4 (compound 11e) is a potent influenza virus neuraminidase inhibitor with IC50s of 3.4, 0.094, 0.79, 0.077 µM for H5N1, H5N2, H5N6, H5N8, respectively. Influenza virus-IN-4 shows NA (neuraminidase enzyme)-inhibitory activity. Influenza virus-IN-4 shows low cytotoxicity with an CC50 of >200 µM. Influenza virus-IN-4 shows no obvious toxicity at the dose of 1500 mg/kg in mice.
  • HY-P1783A
    M2e, human TFA

    Influenza Virus Infection
    M2e, human TFA, consisting of the 23 extracellular residues of M2 (the third integral membrane protein of influenza A), has been remarkably conserved in all human influenza A. M2e, human TFA is a valid and versatile vaccine candidate to protect against any strain of human influenza A.
  • HY-B0338A
    Rimantadine hydrochloride

    Influenza Virus Infection
    Rimantadine hydrochloride is an anti-influenza virus drug.
  • HY-19519
    Ladarixin

    DF 2156A free base

    CXCR Cancer Inflammation/Immunology
    Ladarixin (DF 2156A free base) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin can be used for the research of COPD and asthma.
  • HY-19519A
    Ladarixin sodium

    DF 2156A

    CXCR Infection Inflammation/Immunology
    Ladarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin sodium can be used for the research of COPD and asthma.
  • HY-143757
    Cap-dependent endonuclease-IN-10

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-10 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-10 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo pharmacokinetic and in vivo pharmacodynamic properties, and better hepatic microsomal stability. Cap-dependent endonuclease-IN-10 has the potential for the research of viral infections (including influenza A, influenza B and influenza C) (extracted from patent WO2021129799A1, compound 1-1).
  • HY-109025
    Baloxavir marboxil

    S-033188

    Influenza Virus Infection
    Baloxavir marboxil (S-033188) is a selective inhibitor of influenza cap-dependent endonuclease. Baloxavir marboxil, a potent antiviral agent, shows activity against influenza A and B virus.
  • HY-135853
    Molnupiravir

    EIDD-2801; MK-4482

    SARS-CoV Influenza Virus Infection
    Molnupiravir (EIDD-2801) is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza.
  • HY-B0338
    Rimantadine

    1-Rimantadine

    Influenza Virus Infection
    Rimantadine (Flumadine) is an anti-influenza virus drug.
  • HY-146000
    Influenza virus-IN-3

    Influenza Virus Inflammation/Immunology
    Influenza virus-IN-3 (compound 9) is a potent and selective influenza virus inhibitor with IC50s of 0.88, 0.10, 5.5, 0.51 µM for H5N1, H5N2, H5N6, H5N8, respectively. Influenza virus-IN-3 shows antiviral and NA (neuraminidase enzyme)-inhibitory activity. Influenza virus-IN-3 shows low cytotoxicity with an CC50 of >200 µM.
  • HY-19743
    Triazavirin

    Nucleoside Antimetabolite/Analog Influenza Virus DNA/RNA Synthesis Infection
    Triazavirin is a nucleoside analogue of nucleic acid and an antiviral agent. Triazavirin works by inhibiting the synthesis of viral RNA and DNA and replication of genomic fragments. Triazavirin is also an effective protective agent on the transmission stage of influenza.
  • HY-13318
    Oseltamivir acid

    GS 4071; Ro 64-0802; Oseltamivir carboxylate

    Influenza Virus Drug Metabolite Infection
    Oseltamivir acid (GS 4071), the active metabolite of Oseltamivir phosphate, is an orally bioavailable, potent and selective inhibitor of influenza virus neuraminidase (IC50=2 nM) with activity against both influenza A and B viruses.
  • HY-P0289
    CEF3

    Influenza Virus Infection
    CEF3 (SIIPSGPLK) corresponds to aa 13-21 of the influenza A virus M1 protein. The matrix (M1) protein of influenza A virus is a multifunctional protein that plays essential structural and functional roles in the virus life cycle.
  • HY-126136
    ML303

    Influenza Virus Infection
    ML303 is a pyrazolopyridine influenza virus nonstructural protein 1 (NS1) antagonist (IC90 = 155 nM), with an EC50 of 0.7 μM for Influenza A virus H1N1.
  • HY-122907
    JNJ4796

    Influenza Virus Infection
    JNJ4796 is an oral active fusion inhibitor of influenza virus, neutralizing influenza A group 1 viruses by inhibiting hemagglutinin (HA)-mediated fusion. JNJ4796 mimics the functionality of the broadly neutralizing antibodies (bnAbs).
  • HY-14818AS
    Laninamivir octanoate-d3

    CS-8958-d3

    Influenza Virus Infection
    Laninamivir octanoate-d3 (CS-8958-d3) is the deuterium labeled Laninamivir octanoate. Laninamivir octanoate (CS-8958), a prodrug of Laninamivir, is a long-acting neuraminidase (NA) inhibitor with anti-influenza virus activity. Laninamivir octanoate shows anti-influenza activity against Oseltamivir-resistant viruses, and also against the pandemic influenza viruses.
  • HY-N3016
    Rupestonic acid

    Influenza Virus Infection
    Rupestonic acid, a sesquiterpene, can inhibit influenza virus.
  • HY-50001
    Nucleozin

    Influenza Virus Infection
    Nucleozin, a potent inhibitor of influenza A virus infection, induces the formation of nucleoprotein (NP) aggregates and antagonizes its nuclear accumulation, leading to cessation of viral replication. Nucleozin impedes influenza A virus replication in vitro with a nanomolar EC50.
  • HY-13317S
    Oseltamivir-d3

    Influenza Virus Infection
    Oseltamivir D3 is a deuterium labeled Oseltamivir. Oseltamivir is an influenza virus neuraminidase inhibitor (NAI). Oseltamivir inhibits influenza A/H3N2, A/H1N2, A/H1N1, and B viruses with mean IC50s of 0.67, 0.9, 1.34 and 13 nM, respectively. Anti-influenza A and B agent.
  • HY-135646
    Eleutheroside B1

    Influenza Virus Infection Inflammation/Immunology
    Eleutheroside B1, a coumarin compound, has a wide spectrum of anti-human influenza virus efficacy, with an IC50 value of 64-125 µg/ml. Eleutheroside B1 mediates its anti-influenza activity through POLR2A and N-glycosylation. Eleutheroside B1 inhibits the mRNA expression of several chemokine genes and the influenza nucleoprotein (NP) gene, and exhibits low cytotoxicity. Antiviral and anti-inflammatory activities.
  • HY-109025BS
    Cap-dependent endonuclease-IN-4

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-4 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-4 is a polycyclic carbamoylpyridone derivative. Cap-dependent endonuclease-IN-4 selectively blocks the transcriptional process of influenza virus, thus inhibits influenza virus multiplication. Cap-dependent endonuclease-IN-4 has the potential for the research of colds caused by influenza viruses (extracted from patent WO2019196891A1, compound 1B).
  • HY-17016
    Oseltamivir phosphate

    GS 4104

    Influenza Virus Infection
    Oseltamivir phosphate (GS 4104) is a neuraminidase inhibitor recommended for the treatment and prophylaxis of influenza A and B.
  • HY-147654
    PROTAC Hemagglutinin Degrader-1

    PROTACs Influenza Virus Infection
    PROTAC Hemagglutinin Degrader-1 (Compound V3) is a potent PROTAC influenza hemagglutinin (HA) degrader with a median degradation concentration of 1.44 μM. PROTAC Hemagglutinin Degrader-1 shows broad-spectrum anti-influenza virus activity.
  • HY-13318S
    Oseltamivir acid-d3

    GS 4071-d3; Ro 64-0802-d3; Oseltamivir carboxylate-d3

    Influenza Virus Infection
    Oseltamivir acid D3 (GS 4071 D3) is a deuterium labeled Oseltamivir acid. Oseltamivir acid, the active metabolite of Oseltamivir phosphate, is an orally bioavailable, potent and selective inhibitor of influenza virus neuraminidase (IC50=2 nM) with activity against both influenza A and B viruses.
  • HY-N0243
    Theaflavin

    Influenza Virus Endogenous Metabolite Infection
    Theaflavin is a suitable natural inhibitor against influenza A (H1N1) neuraminidase.
  • HY-112684
    RO-7

    Influenza Virus Infection
    RO-7 is a next-generation polymerase (PA) endonuclease inhibitor of influenza A and B viruses.
  • HY-N0440
    Germacrone

    Influenza Virus Infection
    Germacrone is extracted from Rhizoma Curcuma. Germacrone inhibits influenza virus infection.
  • HY-W015346
    Desaminotyrosine

    3-(4-Hydroxyphenyl)propionic acid

    Influenza Virus Endogenous Metabolite Infection
    Desaminotyrosine is a microbially associated metabolite protecting from influenza through augmentation of type I interferon signaling.
  • HY-141862
    Zanamivir-Cholesterol Conjugate

    Influenza Virus Infection
    Zanamivir–cholesterol conjugate is a long-acting neuraminidase inhibitor with potent efficacy against drug-resistant influenza viruses.
  • HY-N6055
    Nuezhenidic acid

    Others Infection
    Nuezhenidic acid, isolated from the fruits of Ligustrum lucidum, posseses inhibitory activities against influenza A virus.
  • HY-145586
    Onradivir

    Influenza Virus Infection
    Onradivir is a significantly better anti-influenza virus agent extracted from patent WO2021047437 A1.
  • HY-43575
    Oseltamivir-acetate

    Influenza Virus Infection
    Oseltamivir-acetate is an impurity of Oseltamivir. Oseltamivir is a neuraminidase inhibitor recommended for the treatment and prophylaxis of influenza A and B.
  • HY-143769
    Cap-dependent endonuclease-IN-15

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-15 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-15 inhibits the replication of influenza virus. Cap-dependent endonuclease-IN-15 has the potential for the research of viral infections caused by influenza viruses (extracted from patent CN113226327A, compound c-1).
  • HY-B0338S
    Rimantadine-d4 hydrochloride

    Influenza Virus Infection
    Rimantadine-d4 hydrochloride is the deuterium labeled Rimantadine hydrochloride. Rimantadine hydrochloride is an anti-influenza virus agent.
  • HY-115730
    RdRP-IN-3

    Others Infection
    RdRP-IN-3 is a promising anti-influenza drug candidate by inhibiting the activity of RNA-dependent RNA polymerase (RdRp).
  • HY-143768
    Cap-dependent endonuclease-IN-14

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-14 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-14 inhibits the replication of influenza virus. Cap-dependent endonuclease-IN-14 has the potential for the research of viral infections caused by influenza viruses (extracted from patent CN113620948A, compound 1-c).
  • HY-125705
    Herquline A

    Herqueline A

    Influenza Virus Infection Cardiovascular Disease
    Herquline A (Herqueline A) is a fungal piperazine alkaloid. Herquline A is a fungal metabolite that inhibits platelet aggregation and replication of the influenza virus.
  • HY-101950
    KIN1148

    Influenza Virus Infection
    KIN1148, a small-molecule IRF3 agonist, is a novel influenza vaccine adjuvant found to enhance flu vaccine efficacy.
  • HY-12353A
    Pimodivir

    VX-787

    Influenza Virus Infection
    Pimodivir (VX-787) is an orally bioavailable inhibitor of influenza A virus polymerases through interaction with the viral PB2 subunit.
  • HY-B2226
    Sodium copper chlorophyllin B

    HIV Influenza Virus Infection
    Sodium copper chlorophyllin B exerts antiviral activities against Influenza virus and HIV with IC50s of 50 to 100 μM for both of them.
  • HY-111802
    3,4'-Dihydroxyflavone

    3,4'-DHF

    Influenza Virus Infection
    3,4'-Dihydroxyflavone (3,4'-DHF) is an oral active flavonoid with antiviral activity against Influenza A virus.
  • HY-U00160
    SP187

    MON-​DNJ; UV4

    Influenza Virus Infection
    SP187 is a host-targeted iminosugar with activity against filovirus infections in vitro and in vivo. SP187 is active against influenza and dengue in vivo.
  • HY-B0402S
    Amantadine-d15

    1-Adamantanamine-d15; 1-Aminoadamantane-d15

    Influenza Virus Cancer Infection Neurological Disease
    Amantadine-d15 (1-Adamantanamine-d15) is the deuterium labeled Amantadine. Amantadine (1-Adamantanamine) is an antiviral agent with activity against influenza A viruses. Amantadine blocks the proton flow through the M2 ion channel (M2 proton channel of influenza A) and thus prevents the release of viral RNA into the cytoplasm of the infected cells. Amantadine is an antiparkinsonian agent.
  • HY-B0272
    Rifampicin

    Rifampin; Rifamycin AMP

    Bacterial Influenza Virus Antibiotic Orthopoxvirus Infection Cancer
    Rifampicin is a potent and broad spectrum antibiotic against bacterial pathogens. Rifampicin has anti-influenza virus activities. Rifampicin shows anti-orthopoxvirus activity.
  • HY-P0313
    CEF6

    Influenza Virus Infection
    CEF6 is a 9-aa-long peptide corresponding to aa 418-426 of the influenza A virus (H1N1) nucleocapsid protein.
  • HY-N0224
    Epigoitrin

    Influenza Virus Infection Cancer
    Epigoitrin is a natural alkaloid from Isatis indigotica, with antiviral activities. Epigoitrin reduces susceptibility to influenza virus via mitochondrial antiviral signaling.
  • HY-N4194
    Glabrone

    PPAR Metabolic Disease
    Glabrone is an isoflavone isolated from Glycyrrhiza glabra roots. Glabrone exhibits anti-influenza activity and significant PPAR-γ ligand-binding activity.
  • HY-106817
    Amitivir

    LY 217896

    Influenza Virus Infection
    Amitivir (LY 217896), a thiadiazole derivative, possesses broad antiviral activity against orthomyxo- and paramyxoviruses. Amitivir is effective against influenza A and B viruses.
  • HY-136462
    CYM50358

    LPL Receptor Infection
    CYM50358 is a potent and selective S1PR4 antagonist, with an IC50 of 25 nM. CYM50358 can be used for the research of influenza infection.
  • HY-147974
    HSP90-IN-14

    HSP Influenza Virus Infection
    HSP90-IN-14 (compound 4) is a potent Hsp90 (heat shock protein 90) inhibitor, with a Kd of 0.26 μM. HSP90-IN-14 shows anti-influenza virus activity in MDCK cells, with EC50 values of 2.6, 3.9, and 17 μM for influenza A/H3N2, A/H1N1, and B, respectively.
  • HY-143488
    Neuraminidase-IN-8

    Influenza Virus Infection
    Neuraminidase-IN-8 (Compound 6d) is a potent neuraminidase inhibitor with an IC50 of 0.027 µM. Neuraminidase-IN-8 shows anti-influenza activities.
  • HY-15192
    GSK 650394

    SGK Influenza Virus Cancer Infection
    GSK 650394 is a novel SGK inhibitor with IC50 of 62 nM and 103 nM for SGK1 and SGK2 in the SPA assay respectively. GSK 650394 also inhibits influenza virus replication.
  • HY-128965
    N-Glycolylneuraminic acid

    NeuGc; GcNeu

    Influenza Virus Endogenous Metabolite Inflammation/Immunology
    N-Glycolylneuraminic acid is a nonhuman sialic acid molecule synthesized in pigs but not in humans. N-Glycolylneuraminic acid works as a decoy receptor of N-Glycolylneuraminic acid-binding influenza A viruses (IAVs).
  • HY-N0102
    Isoliquiritigenin

    GU17; ISL; Isoliquiritigen

    Aldose Reductase Influenza Virus Autophagy Apoptosis Cancer Infection Inflammation/Immunology
    Isoliquiritigenin is an anti-tumor flavonoid from the root of Glycyrrhiza glabra, which inhibits aldose reductase with an IC50 of 320 nM. Isoliquiritigenin is a potent inhibitor of influenza virus replication with an EC50 of 24.7 μM.
  • HY-137334
    Neuraminidase-IN-1

    Influenza Virus Infection
    Neuraminidase-IN-1 is a neuraminidase inhibitor, with an IC50 of 0.21 μM. Neuraminidase-IN-1 has excellent activity against H1N1 influenza virus.
  • HY-17016S1
    Oseltamivir-d3 phosphate

    GS 4104-d3 phosphate

    Influenza Virus Infection
    Oseltamivir-d3 (GS 4104-d3) phosphateis the deuterium labeled Oseltamivir phosphate. Oseltamivir phosphate (GS 4104) is a neuraminidase inhibitor recommended for the treatment and prophylaxis of influenza A and B.
  • HY-15230
    Geldanamycin

    HSP Bacterial Influenza Virus Antibiotic Cancer Infection Inflammation/Immunology
    Geldanamycin is a Hsp90 inhibitor with antimicrobial activity against many Gram-positive and some Gram-negative bacteria. Geldanamycin has anti-influenza virus H5N1 activities.
  • HY-B0272S2
    Rifampicin-d4

    Rifampin-d4; Rifamycin AMP-d4

    Bacterial Influenza Virus Antibiotic Infection
    Rifampicin-d4 (Rifampin-d4) is the deuterium labeled Rifampicin. Rifampicin is a potent and broad spectrum antibiotic against bacterial pathogens. Rifampicin has anti-influenza virus activities.
  • HY-17016S
    Oseltamivir-d5 phosphate

    GS 4104-d5

    Influenza Virus Infection
    Oseltamivir-d5 phosphate (GS 4104-d5) is the deuterium labeled Oseltamivir phosphate. Oseltamivir phosphate (GS 4104) is a neuraminidase inhibitor recommended for the treatment and prophylaxis of influenza A and B.
  • HY-139558
    Zapnometinib

    PD0184264; ATR-002

    MEK Influenza Virus Bacterial Cancer Infection
    Zapnometinib (PD0184264), an active metabolite of CI-1040, is a MEK inhibitor, with an IC50 of 5.7 nM. Zapnometinib exhibits antiviral activity against influenza virus and antibacterial activities.
  • HY-107902
    RIG-1 modulator 1

    HBV HCV HIV Influenza Virus Infection
    RIG-1 modulator 1 is an anti-viral compound which can be useful for the treatment of viral infections including influenza virus, HBV, HCV and HIV extracted from patent WO 2015172099 A1.
  • HY-N0637
    Eriodictyol

    Huazhongilexone

    Keap1-Nrf2 Influenza Virus DNA/RNA Synthesis Endogenous Metabolite Infection Inflammation/Immunology
    Eriodictyol is a flavonoid isolated from the Chinese herb, with antioxidant and anti-inflammatory activity. Eriodictyol induces Nrf2 signaling pathway. Eriodictyol is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC50 of 18 nM.
  • HY-145391
    Triperiden

    Others Infection
    Triperiden is an inhibitor of influenza virus multiplication. Triperiden targets the haemagglutinin of fowl plague virus (FPV) for antiviral activity and acts by inhibiting the conformational change in the haemagglutinin at acid pH. Triperiden is also anticholinergic anti-parkinsonism drug.
  • HY-B0272S
    Rifampicin-d3

    Bacterial Influenza Virus Antibiotic Infection
    Rifampicin-d3 (Rifampin-d3) is the deuterium labeled Rifampicin. Rifampicin is a potent and broad spectrum antibiotic against bacterial pathogens. Rifampicin has anti-influenza virus activities.
  • HY-144420
    Neuraminidase-IN-5

    Influenza Virus Infection
    Neuraminidase-IN-5 (Compound 5b) is a potent inhibitor of neuraminidase with an IC50 of 0.02 μM. Neuraminidase (NA) is a promising target for development of anti-influenza drugs. Neuraminidase-IN-5 is a dihydrofurocoumarin derivative compound.
  • HY-129150
    Ganoderic acid TR

    Influenza Virus Infection
    Ganoderic acid TR is a broad-spectrum inhibitor against influenza neuraminidases (NAs), particularly H5N1 and H1N1 neuraminidases. The IC50 values of 10.9 and 4.6 μM, respectively.
  • HY-143749
    Cap-dependent endonuclease-IN-6

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-6 (compound 13) is a cap-dependent endonuclease (CEN) inhibitor. Cap-dependent endonuclease-IN-6 shows inhibition against influenza virus (EC50=38.21 nM).
  • HY-111792
    GSK1795091

    CRX-601

    Toll-like Receptor (TLR) Cancer Inflammation/Immunology
    GSK1795091 (CRX-601), an immunologic stimulator, is a synthetic TLR4 agonist. Antitumor activity. GSK1795091 can be used as a vaccine adjuvant to enhance both mucosal and systemic immunity to influenza virus vaccines.
  • HY-138941
    Octaethylene glycol monododecyl ether

    C12E8

    Influenza Virus Infection
    Octaethylene glycol monododecyl ether (C12E8) is an non-ionic detergent that can be used for membrane protein extraction. Octaethylene glycol monododecyl ether can solubilize the viral membrane of intact influenza virus.
  • HY-B0421
    Mycophenolic acid

    Mycophenolate

    Apoptosis Bacterial Fungal Endogenous Metabolite Antibiotic Cancer Infection Inflammation/Immunology
    Mycophenolic acid is a potent uncompetitive inosine monophosphate dehydrogenase (IMPDH) inhibitor with an EC50 of 0.24 µM. Mycophenolic acid demonstrates antiviral effects against a wide range of RNA viruses including influenza. Mycophenolic acid is an immunosuppressive agent. Antiangiogenic and antitumor effects.
  • HY-B0421A
    Mycophenolic acid sodium

    Mycophenolate sodium

    Apoptosis Bacterial Fungal Antibiotic Endogenous Metabolite Cancer Infection Inflammation/Immunology
    Mycophenolic acid sodium is a potent uncompetitive inosine monophosphate dehydrogenase (IMPDH) inhibitor with an EC50 of 0.24 µM. Mycophenolic acid sodium demonstrates antiviral effects against a wide range of RNA viruses including influenza. Mycophenolic acid sodium is an immunosuppressive agent. Antiangiogenic and antitumor effects.
  • HY-147013
    Caprochlorone

    Influenza Virus Orthopoxvirus Infection
    Caprochlorone has antiviral activity against orthopoxvirus. Caprochlorone can inhibit cell penetration by virus, also delays release of newly formed virus from the cell. Caprochlorone decreases the titers of influenza virus in infected-mice lungs.
  • HY-N0224A
    Goitrin

    (S)-Goitrin; L-5-Vinyl-2-thiooxazolidone

    Influenza Virus Metabolic Disease
    Goitrin ((S)-Goitrin), a product of glucosinolate-myrosinase reactions, is a potent inhibitor of thyroid peroxidase. Goitrin can inhibit iodine utilization by the thyroid. Goitrin also exhibits anti-influenza virus (H1N1) activity.
  • HY-12054
    Hesperadin

    Aurora Kinase Autophagy Influenza Virus Parasite Cancer
    Hesperadin is an ATP competitive indolinone inhibitor of Aurora A and B. Hesperadin inhibits Aurora B with an IC50 of 250 nM. Hesperadin inhibits the growth of Trypanosoma brucei by blocking nuclear division and cytokinesis. Hesperadin also is a broad-spectrum influenza antiviral.
  • HY-P1407
    Z-VRPR-FMK TFA

    VRPR

    MALT1 Influenza Virus Cancer Infection
    Z-VRPR-FMK (TFA) (VRPR), a tetrapeptide, is a selective and irreversible MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1) inhibitor. Z-VRPR-FMK (TFA) can protect against influenza A virus (IAV) infection.
  • HY-17015A
    Peramivir

    RWJ-270201; BCX-1812

    Influenza Virus Infection
    Peramivir (RWJ-270201;BCX-1812) is a highly potent, selective and orally active influenza virus neuraminidase (NA) inhibitor, with IC50 values ranging form 0.9 to 4.3 nM for nine NA subtypes.
  • HY-19961
    KIN1408

    HCV Influenza Virus Infection
    KIN1408 is an agonist of the RIG-1-like receptor (RLR) pathway and exhibits a broad-spectrum antiviral activity. KIN1408 exhibits activity against HCV, influenza A, dengue virus 2, Ebola, Nipah, and Lassa viruses.
  • HY-15511
    Tyrphostin A9

    Tyrphostin 9; Malonoben

    VEGFR Influenza Virus Cancer Infection
    Tyrphostin A9, a PDGFR inhibitor, is a potent inducer of mitochondrial fission. Tyrphostin A9 emerged as the most potent and selective of 51 tyrosine kinase inhibitors tested against the TNF-induced respiratory burst. Tyrphostin A9 has anti-influenza virus activities.
  • HY-17015
    Peramivir trihydrate

    RWJ 270201 trihydrate; BCX 1812 trihydrate

    Influenza Virus Infection
    Peramivir trihydrate (RWJ-270201 trihydrate;BCX-1812 trihydrate) is a highly potent, selective and orally active influenza virus neuraminidase (NA) inhibitor, with IC50 values ranging from 0.9 to 4.3 nM for nine NA subtypes.
  • HY-146306
    Neuraminidase-IN-9

    Influenza Virus Infection
    Neuraminidase-IN-9 (Compound 6l) is a potent influenza neuraminidase inhibitor with IC50 values of 0.12, 0.049 and 0.16 µM against H5N1, H5N2 and H5N6, respectively.
  • HY-14768
    Favipiravir

    T-705

    DNA/RNA Synthesis Influenza Virus SARS-CoV Infection
    Favipiravir (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with an IC50 of 341 nM.
  • HY-109025A
    Baloxavir

    Baloxavir acid; S-033447

    Influenza Virus Infection
    Baloxavir (Baloxavir acid), derived from the prodrug Baloxavir marboxil, is a first-in-class, potent and selective cap-dependent endonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir inhibits viral RNA transcription and replication and has potently antiviral activity.
  • HY-N2264
    Wulignan A1

    Influenza Virus Infection
    Wulignan A1 is isolated from the stems of Schisandra henryi. Wulignan A1 exhibits anti-influenza virus H1N1 and H1N1-TR (a Tamiflu drug resistant virus strain) activities.
  • HY-144426
    Neuraminidase-IN-6

    Influenza Virus Infection
    Neuraminidase-IN-6 (Compound 5c) is a potent inhibitor of neuraminidase with an IC50 of 0.11 μM. Neuraminidase-IN-6 is a 1,3,4-triazole-3-acetamide derivative. Neuraminidase (NA) is an ideal target for the development of anti-influenza drugs.
  • HY-N0112
    Dihydromyricetin

    Ampelopsin; Ampeloptin

    mTOR Influenza Virus DNA/RNA Synthesis Autophagy Cancer Infection
    Dihydromyricetin is a potent inhibitor with an IC50 of 48 μM on dihydropyrimidinase. Dihydromyricetin can activate autophagy through inhibiting mTOR signaling. Dihydromyricetin suppresses the formation of mTOR complexes (mTORC1/2). Dihydromyricetin is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC50 of 22 μM.
  • HY-139991
    Neuraminidase-IN-3

    Influenza Virus Infection
    Neuraminidase-IN-3 (compound 23d) is a potent influenza neuraminidase (NA) inhibitor with IC50 values of 0.73, 0.26, and 0.63 nM against H1N1, H5N1, and H5N8 NAs, respectively.
  • HY-143770
    Cap-dependent endonuclease-IN-16

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-16 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-16 is a pyridone polycyclic derivative. Cap-dependent endonuclease-IN-16 has the potential for the research of influenza (extracted from patent CN112778330A, compound 15A).
  • HY-N6025
    Clemastanin B

    Influenza Virus Infection Inflammation/Immunology
    Clemastanin B, a lignin, has potent anti-influenza activities by inhibiting the virus multiplication, prophylaxsis and blocking the virus attachment. Clemastanin B targets viral endocytosis, uncoating or ribonucleoprotein (RNP) export from the nucleus. Clemastanin B has antioxidant and anti-inflammatory activities.
  • HY-N1996
    Chebulagic acid

    COX Lipoxygenase SARS-CoV Influenza Virus Infection Inflammation/Immunology
    Chebulagic acid is a COX-LOX dual inhibitor isolated from the fruits of Terminalia chebula Retz, on angiogenesis. Chebulagic acid is a M2 serine to asparagine 31 mutation (S31N) inhibitor and influenza antiviral. Chebulagic acid also against SARS-CoV-2 viral replication with an EC50 of 9.76 μM.
  • HY-19892
    Brilacidin

    PMX 30063

    Bacterial Antibiotic Infection
    Brilacidin (PMX 30063) is an anti-infective antimicrobial with MIC90s of 1 and 8 μg/mL for Gram-positive bacteria Streptococcus pneumonia and Streptococcus viridans, and MIC90 of 8 and 4 μg/mL for Gram-negative bacteria Haemophilus influenza and Pseudomonas aeruginosa. Brilacidin is a defensin mimetic antibiotic compound.
  • HY-143775
    Cap-dependent endonuclease-IN-20

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-20 is a cap-dependent endonuclease (CEN) inhibitor. Cap-dependent endonuclease-IN-20 shows antiviral activity against influenza virus A/Hanfang/359/95 (H3N2) with IC50 of 4.82 μM (CN112940009A; DSC801).
  • HY-143747
    Cap-dependent endonuclease-IN-5

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-5 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-5 inhibits influenza virus well, and/or has lower cytotoxicity, better in vivo pharmacokinetic properties and in vivo pharmacodynamic properties (extracted from patent WO2020078401A1, compound 13-1).
  • HY-143771
    Cap-dependent endonuclease-IN-17

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-17 is a cap-dependent endonuclease (CEN) inhibitor. Cap-dependent endonuclease-IN-17 shows antiviral activity against influenza virus A/Hanfang/359/95 (H3N2) with IC50 of 1.29 μM (CN112898346A; DSC701).
  • HY-10964
    Vadimezan

    DMXAA; ASA-404

    STING IFNAR Influenza Virus Cancer Infection
    Vadimezan (DMXAA; ASA-404), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan has anti-influenza virus H1N1-PR8 activities.
  • HY-10545
    Taribavirin

    HBV HCV Infection
    Taribavirin is an orally active inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus. Taribavirin, is a ribavirin prodrug, is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia.
  • HY-10545A
    Taribavirin hydrochloride

    HBV HCV Infection
    Taribavirin hydrochloride is an orally active inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus. Taribavirin hydrochloride is a Ribavirin prodrug, is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia.
  • HY-19892A
    Brilacidin tetrahydrochloride

    PMX 30063 tetrahydrochloride

    Bacterial Antibiotic Infection
    Brilacidin tetrahydrochloride (PMX 30063 tetrahydrochloride) is an anti-infective antimicrobial with MIC90s of 1 and 8 μg/mL for Gram-positive bacteria Streptococcus pneumonia and Streptococcus viridans, and MIC90 of 8 and 4 μg/mL for Gram-negative bacteria Haemophilus influenza and Pseudomonas aeruginosa. Brilacidin tetrahydrochloride is a defensin mimetic antibiotic compound.
  • HY-122267
    Clovamide

    trans-Clovamide

    Reactive Oxygen Species Bacterial Influenza Virus Apoptosis Inflammation/Immunology Neurological Disease
    Clovamide (trans-Clovamide), a natural phenolic compound, is a potent antioxidant. Clovamide is an excellent ROS and oxygen radical scavenger. Clovamide also has anti-inflammatory and neuroprotective effects. Clovamide is an anti-microbial with activity against the human pathogens influenza A subtype H5N1, Trypanosoma evansi, and Heliobacter pylori.
  • HY-N0736
    Coptisine chloride

    Indoleamine 2,3-Dioxygenase (IDO) Bacterial Influenza Virus Cancer Infection Metabolic Disease
    Coptisine chloride is an alkaloid from Chinese goldthread, and acts as an efficient uncompetitive IDO inhibitor with a Ki value of 5.8 μM and an IC50 value of 6.3 μM. Coptisine chloride is a potent H1N1 neuraminidase (NA-1) inhibitor with an IC50 of 104.6 μg/mL and can be used for influenza A (H1N1) infection.
  • HY-109025AS
    Baloxavir-d5

    Baloxavir acid-d5; S-033447-d5

    Influenza Virus Infection
    Baloxavir-d5 is deuterium labeled Baloxavir. Baloxavir (Baloxavir acid), derived from the prodrug Baloxavir marboxil, is a first-in-class, potent and selective cap-dependent endonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir inhibits viral RNA transcription and replication and has potently antiviral activity.
  • HY-107201
    β-Cyclodextrin

    Influenza Virus Infection
    β-Cyclodextrin is a cyclic polysaccharide composed of seven units of glucose (α-D-glucopyranose) linked by α-(1,4) type bonds. β-Cyclodextrin has often been used to enhance the solubility of drugs. β-Cyclodextrin has anti-influenza virus H1N1 activities.
  • HY-144103
    Neuraminidase-IN-4

    Influenza Virus Infection
    Neuraminidase-IN-4 (Compound 4b) is a potent inhibitor of neuraminidase with an EC50 of 1.59 μM. Neuraminidase (NA) is an important target for the treatment of influenza. Neuraminidase-IN-4 exhibits excellent antiviral activity against A/chicken/Hubei/327/2004 (H5N1-DW).
  • HY-14904A
    Umifenovir hydrochloride

    Influenza Virus SARS-CoV Infection
    Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an anti-influenza virus agent. Umifenovir hydrochloride could effectively inhibit the fusion of virus with host cells. Umifenovir hydrochloride is an efficient inhibitor of SARS-CoV-2 in vitro. Anti-inflammatory activity.
  • HY-Y1883A
    Triton X-100

    Others Infection
    Triton X-100 is a non-denaturing detergent that solubilizes lipid membranes. Triton X-100 is commonly used in laboratories and is applied to vaccines at different stages of the manufacturing process. Triton X-100 is listed as an excipient in certain vaccines including split virus influenza vaccines. Triton X-100 is a nonionic surfactant.
  • HY-126113
    KIN101

    Influenza Virus HCV Infection
    KIN101 is a potent RNA viral inhibitor with IC50s of 2 μM, >5 μM for influenza virus and Dengue virus (DNV), respectively. KIN101, an isoflavone agonist of IRF-3 dependent signaling, induces IRF-3 nuclear translocation. KIN101 has broad-spectrum activity against RNA viruses.
  • HY-B0215
    Acetylcysteine

    N-Acetylcysteine; N-Acetyl-L-cysteine; NAC

    Reactive Oxygen Species Endogenous Metabolite Apoptosis Ferroptosis Influenza Virus Infection Neurological Disease
    Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases. Acetylcysteine induces cell apoptosis. Acetylcysteine also has anti-influenza virus activities.
  • HY-14904
    Umifenovir

    SARS-CoV Influenza Virus Infection
    Umifenovir is a potent, orally active broad-spectrum antiviral agent with activity against a number of enveloped and non-enveloped viruses. Umifenovir is used as an anti-influenza virus agent. Umifenovir could effectively inhibit the fusion of virus with host cells. Umifenovir is an efficient inhibitor of SARS-CoV-2 in vitro. Umifenovir shows anti-inflammatory activity.
  • HY-N0482
    Phillyrin

    Cytochrome P450 Influenza Virus Bacterial Cancer Infection Inflammation/Immunology
    Phillyrin is isolated from Forsythia suspensa Vahl (Oleaceae), has antibacterial and anti-inflammatory activities. Phillyrin has potential inductive effects on rat CYP1A2 and CYP2D1 activities, without affecting CYP2C11 and CYP3A1/2 activities. Phillyrin has anti-influenza A virus activities.
  • HY-N0761
    Isoferulic acid

    3-Hydroxy-4-methoxycinnamic acid

    Adrenergic Receptor Influenza Virus Infection Endocrinology Metabolic Disease
    Isoferulic acid (3-Hydroxy-4-methoxycinnamic acid) is a cinnamic acid derivative that has antidiabetic activity. Isoferulic acid binds to and activates α1-adrenergic receptors (IC50=1.4 µM) to enhance secretion of β-endorphin (EC50=52.2 nM) and increase glucose use. Isoferulic acid also has anti-influenza virus activities.
  • HY-14904AS
    Umifenovir-d6 hydrochloride

    Influenza Virus SARS-CoV Infection
    Umifenovir-d6 hydrochloride is the deuterium labeled Umifenovir hydrochloride. Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an anti-influenza virus agent. Umifenovir hydrochloride could effectively inhibit the fusion of virus with host cells. Umifenovir hydrochloride is an efficient inhibitor of SARS-CoV-2 in vitro. Anti-inflammatory activity.
  • HY-N2533
    Cyanidin 3-sambubioside chloride

    Cyanidin-3-O-sambubioside chloride

    Influenza Virus Angiotensin-converting Enzyme (ACE) Cancer Infection Inflammation/Immunology
    Cyanidin 3-sambubioside chloride (Cyanidin-3-O-sambubioside chloride), a major anthocyanin, a natural colorant, and is a potent NO inhibitor. Cyanidin 3-sambubioside chloride is a H274Y mutation inhibitor, and inhibits influenza neuraminidase activity with an IC50 of 72 μM. Cyanidin 3-sambubioside chloride inhibits angiotensin-converting enzyme (ACE) activity and has antioxidant, anti-angiogenic and antiviral properties.
  • HY-122920
    Soyasaponin II

    HSV CMV Influenza Virus HIV NOD-like Receptor (NLR) Infection Inflammation/Immunology
    Soyasaponin II is a saponin with antiviral activity. Soyasaponin II inhibits the replication of HSV-1, HCMV, influenza virus, and HIV-1. Soyasaponin II shows potent inhibition on HSV-1 replication. Soyasaponin II serves as a inhibitor for YB-1 phosphorylation and NLRP3 inflammasome priming and could protect mice against LPS/GalN induced acute liver failure.
  • HY-B0402A
    Amantadine hydrochloride

    1-Adamantanamine hydrochloride; 1-Adamantylamine hydrochloride; 1-Aminoadamantane hydrochloride

    Influenza Virus Orthopoxvirus SARS-CoV Apoptosis Bcl-2 Family CDK Cancer Infection Neurological Disease
    Amantadine (1-Adamantanamine) hydrochloride is an orally avtive and potent antiviral agent with activity against influenza A viruses. Amantadine hydrochloride inhibits several ion channels such as NMDA and M2, and also inhibits Coronavirus ion channels. Amantadine hydrochloride also has anti-orthopoxvirus and anticancer activity. Amantadine hydrochloride can be used for Parkinson's disease, postoperative cognitive dysfunction (POCD) and COVID-19 research.
  • HY-B0402
    Amantadine

    1-Adamantanamine; 1-Aminoadamantane

    Influenza Virus Orthopoxvirus SARS-CoV Apoptosis CDK Bcl-2 Family Cancer Infection Neurological Disease
    Amantadine (1-Adamantanamine) is an orally avtive and potent antiviral agent with activity against influenza A viruses. Amantadine inhibits several ion channels such as NMDA and M2, and also inhibits Coronavirus ion channels. Amantadine also has anti-orthopoxvirus and anticancer activity. Amantadine can be used for Parkinson's disease, postoperative cognitive dysfunction (POCD) and COVID-19 research.
  • HY-10496
    SC75741

    NF-κB Influenza Virus Infection Cancer
    SC75741 is a broad and efficient NF-κB inhibitor with an IC50 of 200 nM for p65. SC75741 blocks influenza viruses (IV) replication. SC75741 impairs DNA binding of the NF-κB subunit p65, resulting in reduced expression of cytokines, chemokines, and pro-apoptotic factors. SC75741 subsequently inhibits caspase activation and blocks caspase-mediated nuclear export of viral ribonucleoproteins.
  • HY-N0057
    3,4-Dicaffeoylquinic acid

    3,4-Di-O-caffeoylquinic acid; Isochlorogenic acid B

    Glucosidase Influenza Virus Apoptosis Endogenous Metabolite Cancer Infection
    3,4-Dicaffeoylquinic acid (3,4-Di-O-caffeoylquinic acid), naturally isolated from Laggera alata, has antioxidative, DNA protective, neuroprotective and hepatoprotective properties. 3,4-Dicaffeoylquinic acid exerts apoptosis-mediated cytotoxicity and α-glucosidase inhibitory effects. 3,4-Dicaffeoylquinic acid possesses a unique mechanism of anti-influenza viral activity, that is, enhancing viral clearance by increasing TRAIL.
  • HY-B0157
    Ketotifen

    HC 20-511

    Endogenous Metabolite Histamine Receptor SARS-CoV Influenza Virus Infection Endocrinology Inflammation/Immunology
    Ketotifen (HC 20-511) is an orally active second-generation noncompetitive histamine 1 (H1) receptor blocker and mast cell stabilizer. Ketotifen can block 6-phosphogluconate dehydrogenase (PGD) in vitro. Ketotifen also has antiviral activity against SARS-CoV-2 and influenza virus. Ketotifen can be used to the research of autoimmune encephalomyelitis (EAE) and asthma attack prevention.
  • HY-14818
    Laninamivir

    R 125489

    Influenza Virus Infection
    Laninamivir (R 125489) is a potent influenza neuraminidase (NA) inhibitor with IC50s of 0.90 nM, 1.83 nM and 3.12 nM for avian H12N5 NA (N5), pH1N1 N1 NA (p09N1) and A/RI/5+/1957 H2N2 N2 (p57N2), respectively.
  • HY-143453
    Neuraminidase-IN-7

    Influenza Virus Infection
    Neuraminidase-IN-7 (compound 4b), a thiophene derivative, is a potent neuraminidase inhibitor with an IC50 of 0.03 μM. Neuraminidase-IN-7 also exhibits excellent antiviral activity against A/chicken/Hubei/327/2004 (H5N1-DW) (EC50=1.59 μM). Neuraminidase-IN-7 has the potential for influenza research.
  • HY-B0157A
    Ketotifen fumarate

    HC 20511 fumarate

    Histamine Receptor Endogenous Metabolite Inflammation/Immunology Endocrinology Cancer
    Ketotifen (HC 20-511) fumarate is an orally active second-generation noncompetitive histamine 1 (H1) receptor blocker and mast cell stabilizer. Ketotifen fumarate can block 6-phosphogluconate dehydrogenase (PGD) in vitro. Ketotifen fumarate also has antiviral activity against SARS-CoV-2 and influenza virus. Ketotifen fumarate can be used to the research of autoimmune encephalomyelitis (EAE) and asthma attack prevention.
  • HY-128718
    Carbodine

    Influenza Virus Infection
    Carbodine (Carbocyclic cytidine) is a broad-spectrum antiviral agent active against DNA viruses, (+)RNA viruses, (-)RNA viruses, paramyxo, rhabdo and (+/-)RNA viruses, targets CTP synthetase that converts UTP to CTP. Carbodine (Carbocyclic cytidine) possesses significant antiviral activity against influenza virus types A0/PR-8/34 and A2/Aichi/2/68 in vitro.
  • HY-N0530
    Dryocrassin ABBA

    Dryocrassin

    Influenza Virus Bacterial Infection
    Dryocrassin ABBA (Dryocrassin) is an orally active flavonoid natural product derived from Dryopteris crassirhizoma, with antiviral and antibacterial activities. Dryocrassin ABBA exhibits antiviral activity against H5N1 avian influenza virus. Dryocrassin ABBA inhibits the coagulase activity of Staphylococcus aureus vWbp. Dryocrassin ABBA suppresses immunostimulatory function of dendritic cells and prolongs skin allograft survival.
  • HY-N2532
    Diphyllin

    HIV Proton Pump Influenza Virus Cancer Infection Inflammation/Immunology
    Diphyllin is an arylnaphthalene lignan isolated from Justicia procumbens and is a potent HIV-1 inhibitor with an IC50 of 0.38 μM. Diphyllin is active against vesicular stomatitis virus (VSV) and influenza virus. Diphyllin is a vacuolar type H +-ATPase (V-ATPase) inhibitor with an IC50 value of 17 nM and inhibits lysosomal acidification in human osteoclasts. Diphyllin inhibits NO production with an IC50 of 50 μM and has anticancer and anti-inflammatory activities.
  • HY-B0402B
    Amantadine sulfate

    1-Adamantanamine sulfate; 1-Aminoadamantane sulfate

    Influenza Virus Orthopoxvirus SARS-CoV Apoptosis CDK Bcl-2 Family Cancer Infection Neurological Disease
    Amantadine (1-Adamantanamine) sulfate is an orally avtive and potent antiviral agent with activity against influenza A viruses. Amantadine sulfate inhibits several ion channels such as NMDA and M2, and also inhibits Coronavirus ion channels. Amantadine sulfate also has anti-orthopoxvirus and anticancer activity. Amantadine sulfate can be used for Parkinson's disease, postoperative cognitive dysfunction (POCD) and COVID-19 research.
  • HY-N0540
    Cynaroside

    Luteolin 7-glucoside; Luteolin 7-O-β-D-glucoside

    Influenza Virus DNA/RNA Synthesis Apoptosis Parasite Bacterial Fungal Cancer Infection
    Cynaroside (Luteolin 7-glucoside) is a flavonoid compound that exhibits anti-oxidative capabilities. Cynaroside is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC50 of 32 nM. Cynaroside also is a promising inhibitor for H2O2-induced apoptosis, has cytoprotection against oxidative stress-induced cardiovascular diseases. Cynaroside also has antibacterial, antifungal and anticancer activities, antioxidant and anti-inflammatory activities.
  • HY-125798
    2,3-Dehydro-2-deoxy-N-acetylneuraminic acid

    Neu5Ac2en; DANA

    Influenza Virus Infection
    N-acetyl-2,3-dehydro-2-Deoxyneuraminic Acid (Neu5Ac2en) is a potent neuraminidase (sialidase) inhibitor. N-acetyl-2,3-dehydro-2-Deoxyneuraminic Acid shows inhibitory activities against human neuraminidase enzymes with IC50s of 143, 43, 61, and 74 μM for NEU1, NEU2, NEU3, and NEU4, respectively. Anti-influenza virus activity.
  • HY-109035
    Inarigivir soproxil

    SB9200; GS-9992

    HCV HBV Infection
    Inarigivir soproxil (SB9200) is an agonist of innate immunity and shows potent antiviral activity against resistant HCV variants, with EC50s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems. Inarigivir soproxil, an orally bioavailable prodrug of SB 9000, has broad-spectrum antiviral activity against RNA viruses including HCV, norovirus, respiratory syncytial virus and influenza and HBV.
  • HY-121496
    3M-011

    Toll-like Receptor (TLR) Influenza Virus Cancer Infection Inflammation/Immunology
    3M-011 is a potent dual toll-like receptor TLR7/8 agonist and a cytokine inducer. 3M-011 significantly inhibits H3N2 influenza viral replication in the nasal cavity. 3M-011 is also a potent adjuvant to radiotherapy that induces local and profound systemic immune responses during radiotherapy. 3M-011 strongly has antitumor action.
  • HY-B0215S
    Acetylcysteine-d3

    N-Acetylcysteine-d3; N-Acetyl-L-cysteine-d3; NAC-d3

    Reactive Oxygen Species Endogenous Metabolite Apoptosis Ferroptosis Influenza Virus Infection Neurological Disease
    Acetylcysteine-d3 (N-Acetylcysteine-d3) is the deuterium labeled Acetylcysteine. Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor[1]. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases[5]. Acetylcysteine induces cell apoptosis[2][3]. Acetylcysteine also has anti-influenza virus activities[7].
  • HY-N0638
    Dendrobine

    Influenza Virus Infection
    Dendrobine is an alkaloid isolated from Dendrobium nobile. Dendrobine possesses antiviral activity against influenza A viruses, with IC50s of 3.39 μM, 2.16 μM and 5.32 μM for A/FM-1/1/47 (H1N1), A/Puerto Rico/8/34 H274Y (H1N1) and A/Aichi/2/68 (H3N2), respectively.
  • HY-B0215S1
    Acetylcysteine-15N

    N-Acetylcysteine-15N; N-Acetyl-L-cysteine-15N; NAC-15N

    Reactive Oxygen Species Endogenous Metabolite Apoptosis Ferroptosis Influenza Virus Infection Neurological Disease
    Acetylcysteine-15N (N-Acetylcysteine-15N) is the 15N-labeled Acetylcysteine. Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor[1]. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases[5]. Acetylcysteine induces cell apoptosis[2][3]. Acetylcysteine also has anti-influenza virus activities[7].
  • HY-14818S
    Laninamivir-d3

    Influenza Virus Infection
    Laninamivir-d3 (R 125489-d3) is the deuterium labeled Laninamivir. Laninamivir (R 125489) is a potent influenza neuraminidase (NA) inhibitor with IC50s of 0.90 nM, 1.83 nM and 3.12 nM for avian H12N5 NA (N5), pH1N1 N1 NA (p09N1) and A/RI/5+/1957 H2N2 N2 (p57N2), respectively.
  • HY-100858
    PP7

    Influenza Virus Infection
    PP7 is a potent PB1-PB2 interaction inhibitor with an IC50 of 8.6 μM, and their inhibition against viral polymerase activity (IC50=9.5 μM). PP7 shows antiviral activities against influenza A virus (IAV), including A(H1N1)pdm09 (EC50=1.4 μM), A(H7N9) and A(H9N2) subtypes.
  • HY-122575
    Aurintricarboxylic acid

    P2X Receptor Influenza Virus Topoisomerase MicroRNA Apoptosis Infection Inflammation/Immunology Neurological Disease
    Aurintricarboxylic acid is a nanomolar-potency, allosteric antagonist with selectivity towards αβ-methylene-ATP-sensitive P2X1Rs and P2X3Rs, with IC50s of 8.6 nM and 72.9 nM for rP2X1R and rP2X3R, respectively. Aurintricarboxylic acid is a potent anti-influenza agent by directly inhibiting the neuraminidase. Aurintricarboxylic acid is an inhibitor of topoisomerase II and apoptosis. Aurintricarboxylic acid is a selective inhibitor of the TWEAK-Fn14 signaling pathway. Aurintricarboxylic acid also acts as a cystathionine-lyase (CSE) inhibitor with an IC50 of 0.6 μM. Aurintricarboxylic acid is a modifier of miRNAs that regulate miRNA function, with an IC50 of 0.47 µM.
  • HY-144668
    RdRP-IN-4

    Influenza Virus Infection
    RdRP-IN-4 (compound 11q), an aryl benzoyl hydrazide analog, is an orally active influenza A virus RNA-dependent RNA polymerase (RdRp) inhibitor by interacting with the PB1 subunit. RdRP-IN-4 exhibits potent inhibitory activity against the avian H5N1 flu strain with an EC50 of 18 nM in MDCK cells. RdRP-IN-4 displays excellent potency against the the H1N1 (A/PR/8/34) Flu A strain and Flu B strain (B/Lee/1940) with EC50 values of 53 nM and 20 nM, respectively. RdRP-IN-4 significantly inhibits the expression level of viral nucleoprotein (NP) in a dose-dependent manner. RdRP-IN-4 exhibits significant antiviral activity in infected mice.